SK9282002A3 - Method for the preparation of citalopram, pharmaceutical composition comprising same and intermediates - Google Patents

Method for the preparation of citalopram, pharmaceutical composition comprising same and intermediates Download PDF

Info

Publication number: SK9282002A3
Authority: SK; Slovakia
Prior art keywords: formula; compound; citalopram; prepared; give
Prior art date: 1999-12-28

Application number

SK928-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Hans Petersen

Jakob Felding

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-28

Filing date

1999-12-28

Publication date

2002-11-06

1999-12-28 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2002-11-06 Publication of SK9282002A3 publication Critical patent/SK9282002A3/sk

Links

WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 title claims abstract description 45
229960001653 citalopram Drugs 0.000 title claims abstract description 41
238000000034 method Methods 0.000 title claims abstract description 35
238000002360 preparation method Methods 0.000 title claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 title claims description 5
239000000543 intermediate Substances 0.000 title abstract description 14
150000001875 compounds Chemical class 0.000 claims abstract description 56
238000006243 chemical reaction Methods 0.000 claims abstract description 24
150000003839 salts Chemical class 0.000 claims abstract description 24
239000002253 acid Substances 0.000 claims abstract description 15
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 8
150000001993 dienes Chemical class 0.000 claims abstract description 8
125000000217 alkyl group Chemical group 0.000 claims abstract description 6
229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
229910052717 sulfur Inorganic materials 0.000 claims abstract description 4
125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 18
125000006239 protecting group Chemical group 0.000 claims description 9
239000007818 Grignard reagent Substances 0.000 claims description 8
150000004795 grignard reagents Chemical class 0.000 claims description 8
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
229910052801 chlorine Inorganic materials 0.000 claims description 7
239000000460 chlorine Substances 0.000 claims description 7
230000003647 oxidation Effects 0.000 claims description 7
238000007254 oxidation reaction Methods 0.000 claims description 7
239000012024 dehydrating agents‎ Substances 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
229910052794 bromium Inorganic materials 0.000 claims description 5
150000002431 hydrogen Chemical class 0.000 claims description 4
229910021645 metal ion Inorganic materials 0.000 claims description 4
230000001590 oxidative effect Effects 0.000 claims description 4
UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 claims description 3
BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical class OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
125000003118 aryl group Chemical group 0.000 claims description 3
238000010511 deprotection reaction Methods 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
150000002367 halogens Chemical group 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
229910005965 SO 2 Inorganic materials 0.000 claims description 2
239000012458 free base Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 1
125000003107 substituted aryl group Chemical group 0.000 abstract 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
-1 N, N-dimethylamino Chemical group 0.000 description 11
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
238000003747 Grignard reaction Methods 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000007796 conventional method Methods 0.000 description 6
239000002904 solvent Substances 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
238000007363 ring formation reaction Methods 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-trimethylbenzene Chemical compound CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
239000000935 antidepressant agent Substances 0.000 description 4
ZQFYJHMUAWCEBH-UHFFFAOYSA-N furan-3-carbonitrile Chemical compound N#CC=1C=COC=1 ZQFYJHMUAWCEBH-UHFFFAOYSA-N 0.000 description 4
239000000243 solution Substances 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
239000002841 Lewis acid Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
230000001430 anti-depressive effect Effects 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
239000002585 base Substances 0.000 description 3
125000004093 cyano group Chemical group *C#N 0.000 description 3
150000007517 lewis acids Chemical class 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 3
239000007858 starting material Substances 0.000 description 3
UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 3
AJAGQISKKNDGBS-UHFFFAOYSA-N 1,1-dioxothiophene-3-carbonitrile Chemical compound O=S1(=O)C=CC(C#N)=C1 AJAGQISKKNDGBS-UHFFFAOYSA-N 0.000 description 2
HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000203 mixture Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
QXOXHGUPISQLPW-UHFFFAOYSA-N pyridazine-4-carbonitrile Chemical compound N#CC1=CC=NN=C1 QXOXHGUPISQLPW-UHFFFAOYSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
GSXCEVHRIVLFJV-UHFFFAOYSA-N thiophene-3-carbonitrile Chemical compound N#CC=1C=CSC=1 GSXCEVHRIVLFJV-UHFFFAOYSA-N 0.000 description 2
125000004665 trialkylsilyl group Chemical group 0.000 description 2
LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JDEVKCQFDZTIHC-UHFFFAOYSA-N 1,2-dioxine-4-carbonitrile Chemical compound N#CC1=COOC=C1 JDEVKCQFDZTIHC-UHFFFAOYSA-N 0.000 description 1
UDULCHKNMBLXJG-UHFFFAOYSA-N 1,2-dioxine-4-carboxylic acid Chemical compound OC(=O)C1=COOC=C1 UDULCHKNMBLXJG-UHFFFAOYSA-N 0.000 description 1
YXCRMKYHFFMNPT-UHFFFAOYSA-N 1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound C1=CC(F)=CC=C1C1C2=CC=C(C#N)C=C2CO1 YXCRMKYHFFMNPT-UHFFFAOYSA-N 0.000 description 1
WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
XEEGWTLAFIZLSF-UHFFFAOYSA-N 1-oxo-3h-2-benzofuran-5-carbonitrile Chemical compound N#CC1=CC=C2C(=O)OCC2=C1 XEEGWTLAFIZLSF-UHFFFAOYSA-N 0.000 description 1
VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
LXWLEQZDXOQZGW-UHFFFAOYSA-N 3-bromofuran Chemical compound BrC=1C=COC=1 LXWLEQZDXOQZGW-UHFFFAOYSA-N 0.000 description 1
AZVSIHIBYRHSLB-UHFFFAOYSA-N 3-furaldehyde Chemical compound O=CC=1C=COC=1 AZVSIHIBYRHSLB-UHFFFAOYSA-N 0.000 description 1
IHCCAYCGZOLTEU-UHFFFAOYSA-N 3-furoic acid Chemical compound OC(=O)C=1C=COC=1 IHCCAYCGZOLTEU-UHFFFAOYSA-N 0.000 description 1
IUSPXLCLQIZFHL-UHFFFAOYSA-N 5-bromo-3h-2-benzofuran-1-one Chemical compound BrC1=CC=C2C(=O)OCC2=C1 IUSPXLCLQIZFHL-UHFFFAOYSA-N 0.000 description 1
238000006261 Adler reaction Methods 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
HDDAIFKHTYXICT-UHFFFAOYSA-N CN(C)CCCC1=C(C(=O)C2=CC=CC=C2)C=CC(=C1)F Chemical compound CN(C)CCCC1=C(C(=O)C2=CC=CC=C2)C=CC(=C1)F HDDAIFKHTYXICT-UHFFFAOYSA-N 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
MIOPJNTWMNEORI-MHPPCMCBSA-N [(4r)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-MHPPCMCBSA-N 0.000 description 1
ALIGTYPNWJPIKT-UHFFFAOYSA-M [Cl-].FC1=CC=C([Mg+])C=C1 Chemical compound [Cl-].FC1=CC=C([Mg+])C=C1 ALIGTYPNWJPIKT-UHFFFAOYSA-M 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000011981 lindlar catalyst Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical class C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 1
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
YRTBTTMXMPXJBB-UHFFFAOYSA-N pyridazine-4,5-dicarboxylic acid Chemical compound OC(=O)C1=CN=NC=C1C(O)=O YRTBTTMXMPXJBB-UHFFFAOYSA-N 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
YNVOMSDITJMNET-UHFFFAOYSA-N thiophene-3-carboxylic acid Chemical class OC(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C215/34—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton and at least one hydroxy group bound to another carbon atom of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Furan Compounds (AREA)

SK928-2002A 1999-12-28 1999-12-28 Method for the preparation of citalopram, pharmaceutical composition comprising same and intermediates SK9282002A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/DK1999/000739 WO2001047909A1 (en)	1999-12-28	1999-12-28	Method for the preparation of citalopram

Publications (1)

Publication Number	Publication Date
SK9282002A3 true SK9282002A3 (en)	2002-11-06

Family

ID=8157173

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK928-2002A SK9282002A3 (en)	1999-12-28	1999-12-28	Method for the preparation of citalopram, pharmaceutical composition comprising same and intermediates

Country Status (26)

Country	Link
US (1)	US6762307B2 (bg)
EP (1)	EP1246812B1 (bg)
JP (1)	JP2003519136A (bg)
KR (1)	KR20020073489A (bg)
CN (1)	CN1398263A (bg)
AT (1)	ATE261953T1 (bg)
AU (1)	AU778751B2 (bg)
BG (1)	BG106939A (bg)
CA (1)	CA2395404A1 (bg)
CZ (1)	CZ20022213A3 (bg)
DE (1)	DE69915713T2 (bg)
DK (1)	DK1246812T3 (bg)
EA (1)	EA004742B1 (bg)
ES (1)	ES2219095T3 (bg)
HU (1)	HUP0203635A3 (bg)
IL (1)	IL150335A0 (bg)
IS (1)	IS6435A (bg)
MX (1)	MXPA02006503A (bg)
NO (1)	NO20023126L (bg)
NZ (1)	NZ519739A (bg)
PL (1)	PL355532A1 (bg)
PT (1)	PT1246812E (bg)
SI (1)	SI1246812T1 (bg)
SK (1)	SK9282002A3 (bg)
TR (1)	TR200201678T2 (bg)
WO (1)	WO2001047909A1 (bg)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1173431T4 (da)	1999-04-14	2010-01-04	Lundbeck & Co As H	Fremgangsmåde til fremstilling af citalopram
PT1246813E (pt)	1999-12-30	2004-02-27	Lundbeck & Co As H	Metodo para a preparacao de citalopram
CN1195749C (zh)	2000-01-14	2005-04-06	H.隆德贝克有限公司	制备5－氰基2－苯并[c]呋喃酮的方法
NL1017417C1 (nl)	2000-03-03	2001-03-16	Lundbeck & Co As H	Werkwijze voor de bereiding van Citalopram.
GB0005477D0 (en)	2000-03-07	2000-04-26	Resolution Chemicals Limited	Process for the preparation of citalopram
IES20010206A2 (en)	2000-03-13	2002-03-06	Lundbeck & Co As H	Method for the preparation of citalopram
CN1427835A (zh)	2000-03-13	2003-07-02	H·隆德贝克有限公司	5－取代的1－(4－氟苯基)－1,3－二氢异苯并呋喃的分步烷基化
KR20020080481A (ko)	2000-03-13	2002-10-23	하. 룬트벡 아크티에 셀스카브	시탈로프람의 제조 방법
TR200202155T2 (tr)	2000-03-14	2002-12-23	H. Lundbeck A/S	Sitalopramin preparasyon metodu
AR032455A1 (es)	2000-05-12	2003-11-12	Lundbeck & Co As H	Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
WO2004085416A1 (en) *	2003-03-24	2004-10-07	Hetero Drugs Limited	Novel crystalline forms of (s)-citalopram oxalate
ITMI20040717A1 (it) *	2004-04-09	2004-07-09	Adorkem Technology Spa	Procedimento chemo-enzimatico per la preparazione dell'escitalopram
JP2006008603A (ja) *	2004-06-25	2006-01-12	Sumitomo Chemical Co Ltd	光学活性シタロプラムの製造方法、その中間体およびその製造方法
JP2009515840A (ja) *	2005-11-14	2009-04-16	ハー・ルンドベック・アクチエゼルスカベット	エスシタロプラムの製造方法
WO2009147687A2 (en) *	2008-06-03	2009-12-10	Shodhana Laboratories Limited	An improved process for the separation of enantiomerically pure compounds
US20110092719A1 (en) *	2008-06-16	2011-04-21	Shodhana Laboratories Limited	Preparation of Escitalopram, Its Salts and Intermediates

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1143703A (bg)	1965-03-18
GB1526331A (en) *	1976-01-14	1978-09-27	Kefalas As	Phthalanes
GB8419963D0 (en)	1984-08-06	1984-09-12	Lundbeck & Co As H	Intermediate compound and method
GB8814057D0 (en) *	1988-06-14	1988-07-20	Lundbeck & Co As H	New enantiomers & their isolation
US5296507A (en)	1990-09-06	1994-03-22	H.Lundbeck A/S	Treatment of cerbrovascular disorders
DE19626659A1 (de)	1996-07-03	1998-01-08	Basf Ag	Verfahren zur Herstellung von Phthaliden
DE19627697A1 (de)	1996-07-10	1998-01-15	Basf Ag	Verfahren zur Herstellung von Phthaliden
ES2148120T3 (es)	1997-07-08	2002-01-16	Lundbeck & Co As H	Metodo para la preparacion de citalopram.
UA62985C2 (en)	1997-11-10	2004-01-15	Lunnbeck As H	A method for the preparation of citalopram
EA002770B1 (ru)	1997-11-11	2002-08-29	Х.Лундбекк А/С	Способ получения циталопрама
PL199423B1 (pl)	1998-10-20	2008-09-30	Lundbeck & Co As H	Sposób wytwarzania citalopramu
IL143422A0 (en)	1998-12-23	2002-04-21	Lundbeck & Co As H	Method for the preparation of 5-cyanophthalide
AR022329A1 (es)	1999-01-29	2002-09-04	Lundbeck & Co As H	Metodo para la preparacion de 5-cianoftalida
DK1173431T4 (da)	1999-04-14	2010-01-04	Lundbeck & Co As H	Fremgangsmåde til fremstilling af citalopram
ITMI991579A1 (it)	1999-06-25	2001-01-15	Lundbeck & Co As H	Metodo per la preparazione di citalopram
ITMI991581A1 (it)	1999-06-25	2001-01-15	Lundbeck & Co As H	Metodo per la preparazione di citalopram
GB2360281B (en)	1999-10-25	2002-01-16	Lundbeck & Co As H	Method for the preparation of citalopram
AR026063A1 (es)	1999-11-01	2002-12-26	Lundbeck & Co As H	Metodo para la preparacion de 5-carboxiftalida.
US6310222B1 (en)	1999-11-01	2001-10-30	Sumika Fine Chemicals Co., Ltd.	Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
PT1246813E (pt)	1999-12-30	2004-02-27	Lundbeck & Co As H	Metodo para a preparacao de citalopram
CN1195749C (zh)	2000-01-14	2005-04-06	H.隆德贝克有限公司	制备5－氰基2－苯并[c]呋喃酮的方法
NL1017415C1 (nl)	2000-02-24	2001-05-18	Lundbeck & Co As H	Werkwijze voor de bereiding van Citalopram.
IES20010143A2 (en)	2000-02-24	2001-07-25	Lundbeck & Co As H	Method for the preparation of citalopram
GB0005477D0 (en)	2000-03-07	2000-04-26	Resolution Chemicals Limited	Process for the preparation of citalopram
CA2354877C (en)	2000-08-18	2006-05-02	H. Lundbeck A/S	Method for the preparation of citalopram
WO2001045483A2 (en)	2000-12-22	2001-06-28	H. Lundbeck A/S	Method for the preparation of pure citalopram
JP2003519121A (ja)	2000-12-28	2003-06-17	ハー・ルンドベック・アクチエゼルスカベット	純粋なシタロプラムの製造方法

1999
- 1999-12-28 HU HU0203635A patent/HUP0203635A3/hu unknown
- 1999-12-28 AU AU18583/00A patent/AU778751B2/en not_active Ceased
- 1999-12-28 KR KR1020027008341A patent/KR20020073489A/ko not_active Ceased
- 1999-12-28 DK DK99962132T patent/DK1246812T3/da active
- 1999-12-28 CZ CZ20022213A patent/CZ20022213A3/cs unknown
- 1999-12-28 JP JP2001549379A patent/JP2003519136A/ja not_active Withdrawn
- 1999-12-28 PL PL99355532A patent/PL355532A1/xx not_active Application Discontinuation
- 1999-12-28 DE DE69915713T patent/DE69915713T2/de not_active Expired - Fee Related
- 1999-12-28 AT AT99962132T patent/ATE261953T1/de not_active IP Right Cessation
- 1999-12-28 WO PCT/DK1999/000739 patent/WO2001047909A1/en not_active Ceased
- 1999-12-28 IL IL15033599A patent/IL150335A0/xx unknown
- 1999-12-28 MX MXPA02006503A patent/MXPA02006503A/es not_active Application Discontinuation
- 1999-12-28 TR TR2002/01678T patent/TR200201678T2/xx unknown
- 1999-12-28 CA CA002395404A patent/CA2395404A1/en not_active Abandoned
- 1999-12-28 EP EP99962132A patent/EP1246812B1/en not_active Expired - Lifetime
- 1999-12-28 SK SK928-2002A patent/SK9282002A3/sk unknown
- 1999-12-28 CN CN99817098A patent/CN1398263A/zh active Pending
- 1999-12-28 ES ES99962132T patent/ES2219095T3/es not_active Expired - Lifetime
- 1999-12-28 PT PT99962132T patent/PT1246812E/pt unknown
- 1999-12-28 EA EA200200719A patent/EA004742B1/ru not_active IP Right Cessation
- 1999-12-28 SI SI9930567T patent/SI1246812T1/xx unknown
- 1999-12-28 NZ NZ519739A patent/NZ519739A/en unknown
2002
- 2002-06-19 IS IS6435A patent/IS6435A/is unknown
- 2002-06-25 US US10/183,958 patent/US6762307B2/en not_active Expired - Fee Related
- 2002-06-27 NO NO20023126A patent/NO20023126L/no not_active Application Discontinuation
- 2002-07-22 BG BG106939A patent/BG106939A/bg unknown

Also Published As

Publication number	Publication date
BG106939A (bg)	2003-03-31
KR20020073489A (ko)	2002-09-26
HUP0203635A3 (en)	2005-02-28
HUP0203635A2 (hu)	2003-02-28
AU1858300A (en)	2001-07-09
MXPA02006503A (es)	2002-12-09
DK1246812T3 (da)	2004-07-05
DE69915713D1 (de)	2004-04-22
DE69915713T2 (de)	2005-03-03
EP1246812A1 (en)	2002-10-09
PT1246812E (pt)	2004-08-31
ATE261953T1 (de)	2004-04-15
NZ519739A (en)	2004-03-26
JP2003519136A (ja)	2003-06-17
US20030060641A1 (en)	2003-03-27
EA004742B1 (ru)	2004-08-26
NO20023126D0 (no)	2002-06-27
IL150335A0 (en)	2002-12-01
EP1246812B1 (en)	2004-03-17
WO2001047909A1 (en)	2001-07-05
CN1398263A (zh)	2003-02-19
IS6435A (is)	2002-06-19
AU778751B2 (en)	2004-12-16
EA200200719A1 (ru)	2002-12-26
US6762307B2 (en)	2004-07-13
PL355532A1 (en)	2004-05-04
NO20023126L (no)	2002-06-27
TR200201678T2 (tr)	2002-10-21
ES2219095T3 (es)	2004-11-16
CZ20022213A3 (cs)	2002-09-11
CA2395404A1 (en)	2001-07-05
SI1246812T1 (en)	2004-08-31

Legal Events

Date	Code	Title	Description
2010-02-08	FB9A	Suspension of patent application procedure

Publication	Publication Date	Title
EP1173431B1 (en)	2003-04-16	Method for the preparation of citalopram
US6750358B2 (en)	2004-06-15	Method for the preparation of citalopram
SK9282002A3 (en)	2002-11-06	Method for the preparation of citalopram, pharmaceutical composition comprising same and intermediates
US20020004604A1 (en)	2002-01-10	Method for the preparation of citalopram
US6660873B2 (en)	2003-12-09	Method for the preparation of citalopram
AU2001258239A1 (en)	2002-02-07	Method for the preparation of citalopram
HRP20020562A2 (en)	2003-10-31	Method for the preparation of citalopram
ZA200204916B (en)	2003-09-23	Method for the preparation of citalopram.
HK1051689A (en)	2003-08-15	Method for the preparation of citalopram
ZA200107956B (en)	2002-11-27	Method for the preparation of citalopram.